Welcome to our dedicated page for AI / ML Innovations news (Ticker: AIMLF), a resource for investors and traders seeking the latest updates and insights on AI / ML Innovations stock.
AI/ML Innovations Inc. develops artificial intelligence and neural-network technology for digital health applications. The company’s platforms use signal processing and deep learning to convert biometric data into clinical insights, with recurring updates centered on ECG analysis, heart rate variability analytics, remote cardiac monitoring, and cardiovascular research support.
News for AIMLF also covers activity at its Neural Cloud Solutions subsidiary, including MaxYield™, CardioYield™, and Insight 360™ commercialization, reseller and distribution agreements, research-services collaborations, medical advisory board appointments, and capital-structure actions such as private placements, convertible debentures, warrants, options, and share issuances for debt settlement.
AI/ML Innovations (OTCQB:AIMLF) has successfully completed an oversubscribed non-brokered private placement, raising $2,128,595 through the issuance of 42,571,900 Units at $0.05 per Unit. Each Unit includes one common share and one warrant exercisable at $0.15 until September 22, 2030.
Notable insider participation included CEO Paul Duffy (5M Units), President Peter Kendall (500K Units), CPO Esmatullah Naikyar (120K Units), and major shareholder Sheldon Inwentash (26M Units). Additionally, the company extended the expiry date of 12,376,666 December 2023 Warrants to December 19, 2028, and granted 5,700,000 stock options to officers, employees, and consultants at $0.10 per share.
AI/ML Innovations (OTCQB:AIMLF) has announced plans for a non-brokered private placement offering of up to 31,000,000 units at $0.05 per unit, aiming to raise gross proceeds of up to $1.55 million.
Each unit consists of one common share and one warrant, with each warrant exercisable at $0.15 per share for a five-year term. The securities will have a four-month and one-day hold period. The company plans to use the proceeds for working capital requirements and will pay finder's fees to qualified finders. The private placement remains subject to necessary approvals, including from the Canadian Securities Exchange.
AI/ML Innovations (OTCQB:AIMLF) has filed an amended and restated management's discussion and analysis (MD&A) for the periods ending January 31, 2025, following a review by the British Columbia Securities Commission. The amended filing addresses several disclosure deficiencies.
The enhanced disclosure includes details about new strategic initiatives, R&D activities, operational results, and the acquisition of Quantum Sciences Ltd. Additional information covers related party payments, an exit agreement with Tech2Heal, and other minor updates. The complete Amended MD&A is accessible on SEDAR+.
AI/ML Innovations (OTCQB:AIMLF) has announced the completion of its restructuring related to the previously acquired Quantum Sciences Ltd. The restructuring, which follows the original acquisition from December 23, 2024, includes key modifications to the initially announced terms.
Two notable changes from the original restructuring announcement include: (1) the non-execution of a planned reseller agreement with Mark Orsmond, and (2) the retention of all intellectual property rights and interests in the "meApp" application by AIML, rather than transferring them to Mark Orsmond as previously planned.
AIML (AIMLF) has announced the formation of its Medical Advisory Board to guide the development and implementation of its AI-powered ECG signal-processing platforms MaxYield™ and CardioYield™. The board comprises six distinguished cardiovascular experts from leading institutions, including the University of Toronto and University of British Columbia. Peter Kendall, AIML's President and Chief Commercialization Officer, will chair the board, leveraging his 20+ years of experience in health technology commercialization.
The advisory board will focus on steering clinical direction, trial design, and real-world deployment of AIML's flagship AI platforms. Simultaneously, the company has launched its redesigned corporate website, AIML.Health, serving as an interactive platform for stakeholders.
AI/ML Innovations (AIML) has submitted a 510(k) premarket notification to the FDA for its MaxYield™ platform, a cloud-native solution designed to enhance ECG signal quality. The platform uses proprietary neural network algorithms to reduce noise and improve waveform clarity in ECG signals across 1- to 12-lead configurations for adult patients 18 and older.
MaxYield is compatible with both hospital-grade systems and mobile devices, targeting signal distortions common in mobile, wearable, and dynamic clinical environments. This submission follows AIML's prior Device Master File (MAF) filing, which could facilitate future collaborations with manufacturers for device integration.
Additionally, AIML granted 800,000 stock options to directors and consultants at an exercise price of $0.105, vesting quarterly over one year with a five-year expiration.
AIML Innovations (OTCQB: AIMLF) has appointed Michael Diamond to its Board of Directors, effective immediately. Diamond, who serves as the President of the Ontario Progressive Conservative Party and Principal of Upstream Strategy Group, brings extensive expertise in political strategy, regulatory affairs, and stakeholder engagement. The appointment aims to strengthen AIML's expansion of AI-powered health technologies across regulated markets.
As a public affairs and strategic communications expert, Diamond's experience at the intersection of politics, business, and innovation will support AIML's efforts to build partnerships and navigate policy environments. The company, through its subsidiaries and strategic partnerships, focuses on AI and machine learning applications in digital health and wellbeing solutions.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) announced the immediate departure of Tim Daniels from its Board of Directors. While stepping down from the Board, Daniels will continue supporting the company in an advisory capacity.
CEO Paul Duffy acknowledged Daniels' contributions to AIML's leadership and strategic direction during his tenure, expressing appreciation for his continued involvement as an advisor. The company stated it remains focused on strengthening its leadership and advisory network to support ongoing commercialization efforts and strategic growth initiatives.
AIML operates in the artificial intelligence and machine learning sectors, focusing on digital health and wellbeing solutions through its subsidiaries NeuralCloud Solutions, Quantum Sciences, AI Rx, and strategic partnership with Health Gauge (95.2% owned by AIML).